29.12.2014

International journal of cancer immunology immunotherapy impact factor

The awards recognize not only his research accomplishments, but also the growing influence the field of immunotherapy has gained in the past few years, said Allison, a professor and chair in the Department of Immunology at the University of Texas MD Anderson Cancer Center, in an interview with OncLive. Allison himself has been dedicated to understanding the immune system, and the specific role T cells play in it, for most of his career. While continuing his research into T-cell response mechanisms, Allison discovered that blocking signaling of the immune-checkpoint protein CTLA-4 improved antitumor immune responses. The discovery of the immune checkpoint blockade strategy and the subsequent approval of ipilimumab have changed the course of Allison’s career. Recently, the FDA accepted a supplemental biologics license application for ipilimumab as an adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.
Multiple clinical trials have also been investigating ipilimumab with the oncolytic virus T-VEC, which was recently recommended for approval by the FDA’s Oncologic Drugs Advisory Committee (ODAC) and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC). One phase Ib study showed an ORR with the combination of T-VEC and ipilimumab was 56% in patients with advanced melanoma.


Allison believes ipilimumab has the most potential when used in combination with other agents, but additional research is required before this can truly be successful.
Allison’s lab is aiming to combat this lack of understanding by investigating checkpoint inhibitor combinations by pairing them with each other, as well as with oncologic viruses, radiation, targeted therapies, and chemotherapy.
He is also interested in checkpoint inhibitor combinations that can be used to treat tumors with lower mutation loads, such as those seen in kidney and prostate cancer. Follow UsMelanoma Google AlertsMelanoma Google Alerts is a summary of daily articles found in print and on the internet.
Allison, PhD, who pioneered the checkpoint blockade strategy that led to the development of ipilimumab (Yervoy) and other immunotherapy agents, was recently honored with two prestigious awards: the Science of Oncology Award from ASCO and the Pezcoller Foundation–AACR International Award for Cancer Research. In 1982, while he was working at MD Anderson Cancer Center (then named University of Texas System Cancer Center), he became the first scientist to determine how T cells recognize alien proteins within the body. His lab went on to develop an antibody against CTLA-4, which inhibited tumor growth in mice.


Patients treated with ipilimumab alone had a median OS of 10 months, while those treated with gp100 had a median OS of 6 months. The phase II CheckMate-069 trial, which was recently presented at the 2015 AACR Annual Meeting, showed that nivolumab (Opdivo) plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma. This discovery led to the development of ipilimumab, which blocks the inhibitor function of CTLA-4, allowing T cells to attack and eliminate cancer cells. The checkpoint inhibitor combination had an overall response rate (ORR) of 61% in a subgroup of BRAF V600 wild-type (WT) patients.
In 2011, ipilimumab became the first immune checkpoint inhibitor approved by the FDA when it was authorized for use as a treatment for patients with advanced melanoma.



Organic chinese herbs canada
Treatment of early prostate cancer
Home remedies for anti cancer uterino
Cancer orthomolecular medicine


Comments to «International journal of cancer immunology immunotherapy impact factor»

  1. 10_Uj_040 writes:
    Chinese angelica, mentioned to nourish the.
  2. Sanoy writes:
    Harper, an imprint when the plaster fully overlaying one leg private tales and no trustworthy analysis, the.
  3. tana writes:
    And Moxibustion Of Traditional Chinese Medicine effective for weight loss having all the time been.
  4. Naina writes:
    Could be very safe and some various therapies.
  5. hmmmmmm writes:
    Cancer care within the state of Rio Grande do Sul, creating initiatives.